Phase III Randomized Controlled Trial of JDQ443 Versus Docetaxel in KRAS G12C Mutant Advanced Non-Small Cell Lung Cancer
- Trial ID
- 2023-510082-10-00
- Protocol
- CJDQ443B12301
- Sponsor
- Novartis Pharma AG
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this phase III study is to evaluate the **progression-free survival (PFS)** of JDQ443 compared to docetaxel in subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer. This is clinically relevant as PFS is a critical endpoint in oncology trials, reflecting the time during which a patient's disease does not worsen, thus providing insights into the efficacy of JDQ443 as a potential treatment option.
Secondary objectives include characterizing the safety profile of JDQ443 in study participants, including those who crossover from docetaxel. Understanding the safety profile is essential for assessing the risk-benefit ratio of JDQ443, ensuring that any adverse effects are identified and managed appropriately in the clinical setting.
Participants
The clinical trial involves a total of **180 participants** diagnosed with **advanced non-small cell lung cancer** harboring the **KRAS G12C mutation**. The study population includes both male and female subjects aged 18 years and older. Participants have a histologically confirmed diagnosis of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer, having received at least one but not more than three previous lines of treatment, including prior platinum-based chemotherapy and immune checkpoint inhibitor therapy. The trial population was selected based on the presence of the KRAS G12C mutation, confirmed through central laboratory testing or local laboratory assessments. Participants exhibit an Eastern Cooperative Oncology Group (ECOG) performance status ranging from 0 to 2, indicating varying levels of general health status. The trial includes a vulnerable population, and lifestyle considerations such as diet and physical activity are not specified in the available data.
Plans and Procedures
The clinical trial is a **randomized**, controlled, open-label, phase III study designed to evaluate the efficacy and safety of JDQ443 compared to **docetaxel** in patients with locally advanced or metastatic **KRAS G12C mutant non-small cell lung cancer**. The primary objective is to assess progression-free survival (PFS) as per RECIST 1.1 criteria, with secondary endpoints including the type, frequency, and severity of adverse events, as well as changes in laboratory values, vital signs, and ECGs. The trial is expected to run from June 15, 2022, to December 30, 2025, with a maximum treatment period of 1294 days for participants.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, disease stage, and previous treatment history. Eligible participants must be 18 years or older, have histologically confirmed locally advanced or metastatic KRAS G12C-mutant NSCLC, and have received prior treatments including platinum-based chemotherapy and immune checkpoint inhibitors. The study will include regular follow-up visits to monitor treatment response and safety, with assessments conducted by investigators. The end-of-study visit will conclude the participant's involvement, during which final evaluations will be performed.
Participant involvement is expected to last up to the maximum treatment period, with conditions for early termination including disease progression, unacceptable toxicity, or withdrawal of consent. The trial will adhere to rigorous scientific and ethical standards to ensure the validity and reliability of the results, contributing valuable data to the understanding and management of advanced non-small cell lung cancer with KRAS G12C mutations.
Treatment
The clinical trial involves the evaluation of three treatments, including the experimental medication **JDQ443**. JDQ443 is administered in the form of a **tablet** and is taken orally. The maximum daily dose is 400 mg, with a total maximum dose of 517.6 g over the treatment period. The treatment duration is set for a maximum of 1294 days. JDQ443 is a chemical compound with the active substance 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one, developed by Novartis Pharma AG.
The comparator treatment in the study is **Docetaxel**, which is administered intravenously. The pharmaceutical form of Docetaxel is denoted as PHF00230MIG. The maximum daily dose is 75 mg/m², with a total maximum dose of 4575 mg/m² over the treatment period. The administration of Docetaxel is subject to local regulations and may be relabeled to include the study code or kit number if centrally sourced by the local country office. The treatment duration is also set for a maximum of 1294 days.
Additionally, the study includes a non-experimental treatment involving **Glucocorticoids**, administered orally. The pharmaceutical form is indicated as PHF00231MIG. The maximum daily dose is 16 mg, with a total maximum dose of 2928 mg over the treatment period. The treatment duration is consistent with the other treatments, set for a maximum of 1294 days. Monitoring of participant compliance with the dosing schedules is integral to the study protocol to ensure accurate assessment of treatment efficacy and safety.
Efficacy
The efficacy of the clinical trial titled "KontRASt-02: A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic **KRAS G12C mutant non-small cell lung cancer**" will be assessed primarily through the measurement of **progression-free survival (PFS)**. This primary endpoint will be evaluated according to the RECIST 1.1 criteria as assessed by the investigator. The trial aims to compare the efficacy of JDQ443 against docetaxel in the specified patient population.
Secondary endpoints include the assessment of the type, frequency, and severity of adverse events, as well as changes in laboratory values, vital signs, and ECGs. These parameters will be collected and analyzed to provide a comprehensive evaluation of the treatment's safety profile alongside its efficacy. The trial is designed to ensure rigorous monitoring and data collection to support the evaluation of these endpoints.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Participants are male and female, aged 18 or older
- Histologically confirmed locally advanced (stage IIIB/IIIC not eligible for definitive chemoradiation or surgical resection with curative intent) or metastatic (stage IV) previously treated KRAS G12C-mutant NSCLC. Presence of a KRAS G12C mutation by central laboratory testing using tissue or blood samples, or assessed locally with GuardantHealth Guardant360® CDx liquid biopsy test or by a local laboratory utilizing the QIAGEN therascreen® KRAS RGQ PCR kit
- Participants have received at least 1, but not more than 3, previous lines of treatment including one prior platinum-based chemotherapy and one prior immune checkpoint inhibitor therapy either in combination or in sequence
- Participants with ECOG performance status from 0 to 2
Exclusion Criteria
- Participants who have previously received docetaxel (except if received in neoadjuvant or adjuvant setting with no progression within 12 months after the of end of treatment), or any other KRAS G12C inhibitor
- Participants whose tumors harbor an epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) rearrangement by local testing. Participants with other known druggable alterations will be excluded, if required by local guidelines
- History of severe hypersensitivity reaction to taxanes or any excipients of these study treatments
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Finland | Not Recruiting | 15 Jun 2022 | 5 |
Greece | Not Recruiting | 15 Jun 2022 | 4 |
Hungary | Not Recruiting | 15 Jun 2022 | 5 |
Iceland | Not Recruiting | 15 Jun 2022 | 2 |
Italy | Not Recruiting | 15 Jun 2022 | 12 |
Portugal | Not Recruiting | 15 Jun 2022 | 8 |
Romania | Not Recruiting | 15 Jun 2022 | 10 |
Slovenia | Not Recruiting | 15 Jun 2022 | 8 |
Spain | Not Recruiting | 15 Jun 2022 | 14 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
- | Other | PHF00231MIG | ORAL | 16 | 1294 | H02AB |
JDQ443 | Test | TABLET | ORAL | 400 | 1294 | PRD10717130 |
DOCETAXEL | Comparator | PHF00230MIG | INTRAVENOUS | 75 | 1294 | SCP126226 |









